Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

32.36
-1.7100-5.02%
Volume:481.13K
Turnover:16.09M
Market Cap:1.26B
PE:-13.59
High:34.20
Open:33.50
Low:32.19
Close:34.07
52wk High:37.48
52wk Low:3.59
Shares:38.87M
Float Shares:29.65M
Volume Ratio:2.69
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3816
EPS(LYR):-2.1918
ROE:-49.17%
ROA:-26.79%
PB:5.74
PE(LYR):-14.76

Loading ...

Alto Neuroscience to Present at H.C. Wainwright Global Healthcare Conference

Reuters
·
Sep 09

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

THOMSON REUTERS
·
Aug 28

Alto Neuroscience Lawsuit Dismissed for Now, With Investors Given Chance to Amend Claims

TIPRANKS
·
Aug 22

Alto Neuroscience Price Target Raised to $55.00/Share from $50.00 by HC Wainwright & Co.

Dow Jones
·
Aug 18

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright

TIPRANKS
·
Aug 17

Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?

Simply Wall St.
·
Aug 16

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14

BofA Adjusts Price Target on Alto Neuroscience to $37 From $33

MT Newswires Live
·
Aug 14

Alto Neuroscience, Inc. (ANRO) Receives a Buy from Jefferies

TIPRANKS
·
Aug 13

Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Alto Neuroscience Inc : Jefferies Raises Target Price to $40 from $35

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)

TIPRANKS
·
Aug 13

Alto Neuroscience Posts Corporate Presentation Outlining Precision Psychiatry Drug Pipeline, Led by ALTO-207 in Treatment-Resistant Depression

Reuters
·
Aug 13

Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate

Benzinga Earnings
·
Aug 13

Alto Neuroscience Q2 Net Loss Widens to $27.64 Million; R&D Expenses Rise to $22.11 Million

Reuters
·
Aug 13

Press Release: Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Aug 13

Alto Neuroscience Raises Capital to Advance ALTO-207

TIPRANKS
·
Jul 15

Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials

TIPRANKS
·
Jul 13

Alto Neuroscience Sets Pricing for $100 Million Registered Direct Offering of Common Stock

Deep News
·
Jul 13